Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
http://img.marketwire.com/rss/mwPBTR.rss
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
announced  cancer  clinical stage  clinical  company  december  drug  marketwired december  marketwired  moleculin  nasdaq  new  patent 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials



Marketwired - Trials



Last Build Date: Fri, 08 Dec 2017 09:31:16 EST

Copyright: Copyright: (C) Marketwired
 



VistaGen Therapeutics Expands Stem Cell Patent Portfolio with New U.S. Patent on Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer

Fri, 08 Dec 2017 09:00:00 EST

SOUTH SAN FRANCISCO, CA--(Marketwired - December 08, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,834,754 related to methods for producing, from human pluripotent stem cells (hPSCs), hematopoietic precursor stem cells, which are stem cells that give rise to all of the blood cells and most of the bone marrow cells in the body. VistaGen holds an exclusive license to this patent from the University Health Network (UHN).




ANGLE plc Announces Parsortix Potential in Metastatic Breast Cancer

Fri, 08 Dec 2017 02:00:00 EST

GUILDFORD, SURREY--(Marketwired - Dec 8, 2017) - ANGLE plc (AIM: AGL) (OTCQX: ANPCY)




Pieris Pharmaceuticals Announces Ethics and Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory Program, PRS-060/AZD1402

Thu, 07 Dec 2017 08:30:00 EST

BOSTON, MA--(Marketwired - December 07, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it has received approval from the Human Research Ethics Committee and authority from the Therapeutic Goods Administration to initiate its first-in-human study in Australia for PRS-060/AZD1402, an inhaled Anticalin protein that targets IL-4R? for the treatment of moderate to severe asthmatic patients that are not controlled on standard of care. This phase 1 study will be conducted in healthy subjects and is being developed as part of Pieris' strategic alliance with AstraZeneca, which is funding the trial, with Pieris being responsible for conducting the study.




Critical Outcome Technologies Annual and Special Meeting of Shareholders Rescheduled

Wed, 06 Dec 2017 17:45:35 EST

LONDON, ONTARIO and BOSTON, MASSACHUSETTS--(Marketwired - Dec. 6, 2017) - Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced a change in the previously set date for the Company's Annual and Special Meeting of Shareholders (the "Meeting"), which was originally scheduled for Thursday, December 7, 2017 at 9:30 a.m. Eastern Standard Time.




Moleculin's WP1066 Drug receives $2 million Private Grant

Wed, 06 Dec 2017 10:01:00 EST

HOUSTON, TX--(Marketwired - December 06, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), announced that its WP1066 drug will receive $2 million in private grant funding for its recently announced Investigational New Drug ("IND") clearance for a physician-sponsored Phase I trial of Moleculin's drug WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma.




VistaGen Therapeutics Granted U.S. Patent regarding Methods of Production for AV-101

Wed, 06 Dec 2017 09:08:09 EST

SOUTH SAN FRANCISCO, CA--(Marketwired - December 06, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,834,801 related to certain methods of production for AV-101, VistaGen's lead CNS product candidate.




Vernalis and Servier Achieve Research Milestone

Wed, 06 Dec 2017 02:00:00 EST

WINNERSH, UNITED KINGDOM--(Marketwired - Dec 6, 2017) - Vernalis PLC (LSE: VER)




Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tue, 05 Dec 2017 16:01:00 EST

BERKELEY, CA--(Marketwired - December 05, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that on November 28, 2017 the Compensation Committee of Dynavax's Board of Directors approved (i) the grant of inducement stock options to purchase an aggregate 73,800 shares of common stock and (ii) an inducement restricted stock unit award covering an aggregate of 1,000 shares of common stock, to six new employees. These awards were granted pursuant to the Dynavax Technologies Corporation Inducement Plan, as an inducement material to the new employees entering into employment with Dynavax, in accordance with the NASDAQ Listing Rule 5635(c)(4).




New Aurora Advanced Flow Cytometry System from Cytek Biosciences Resonates with Researchers Around the World

Tue, 05 Dec 2017 10:00:00 EST

Systems Purchased by Laboratories on Four Continents -- and Counting




IntelGenx to Regain Exclusive Worldwide Rights to Develop and Commercialize RIZAPORT(R)

Tue, 05 Dec 2017 09:30:00 EST

FDA Requests More Information Before Full Review of RIZAPORT(R) NDA Resubmission




Vaxil Strengthens Board of Directors and Management Concurrent to $1-Million Financing

Tue, 05 Dec 2017 08:30:00 EST

NESS-ZIONA, ISRAEL--(Marketwired - December 05, 2017) - VAXIL BIO LTD. (TSX VENTURE: VXL), an innovative Israeli immuno-oncology biotechnology company, is pleased to announce the addition of two veteran healthcare executives to its Board of Directors. Dr. Ari Kellen, formerly of McKinsey & Company, Bausch + Lomb, and Valeant; together with Dr. Shawn Langer, formerly of McKinsey & Company, and a current healthcare private equity portfolio manager with BMHS Investments, have joined Vaxil's Board of Directors. Director Mr. Isaac Maresky, an investment banking professional with hundreds of millions of dollars of financings and M&A experience, including co-founding another successful immunotherapy company, has been appointed CEO of Vaxil.




Moleculin's WP1066 Drug gets FDA Brain Tumor IND Clearance

Tue, 05 Dec 2017 07:00:00 EST

HOUSTON, TX--(Marketwired - December 05, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), announced the physician-sponsored Investigational New Drug ("IND") application for a Phase I trial of Moleculin's drug WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma has been allowed by the US Food and Drug Administration ("FDA").




Preclinical Efficacy Data on Sickle Cell Disease of ORY-3001, a LSD1 inhibitor from ORYZON, to be presented at ASH 2017

Mon, 04 Dec 2017 08:00:00 EST

MADRID, SPAIN and CAMBRIDGE, MA--(Marketwired - December 04, 2017) -

  • Research in mice and baboons has been done by the University of Illinois at Chicago
  • Oral Presentation on December 10th to be delivered by Prof. D. Lavelle
  • Oryzon's CEO will attend the Conference



Looking Beyond Risk in Risk-Based Monitoring, New Webinar Hosted by Xtalks

Mon, 04 Dec 2017 07:30:00 EST

Fourth in the series Four Steps to Shorten Your Clinical Trials with Informatics




Trillium Announces Closing of Private Placement

Fri, 01 Dec 2017 22:21:15 EST

TORONTO, ONTARIO--(Marketwired - Dec. 1, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its non-brokered private placement, previously announced on November 15, 2017, of 1,950,000 common shares and 400,000 Series II non-voting convertible first preferred shares at a price of U.S.$8.50 per share for gross proceeds of U.S.$19,975,000.